These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 3035392)

  • 1. Plasma levels of main granulocyte components in patients dialyzed with polycarbonate and cuprophan membranes.
    Hörl WH; Riegel W; Schollmeyer P
    Nephron; 1987; 45(4):272-6. PubMed ID: 3035392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different complement and granulocyte activation in patients dialyzed with PMMA dialyzers.
    Hörl WH; Riegel W; Schollmeyer P; Rautenberg W; Neumann S
    Clin Nephrol; 1986 Jun; 25(6):304-7. PubMed ID: 3015463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte activation during hemodialysis.
    Hörl WH; Riegel W; Steinhauer HB; Wanner C; Thaiss F; Bozkurt F; Haag M; Schollmeyer P
    Clin Nephrol; 1986; 26 Suppl 1():S30-4. PubMed ID: 3829465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of granulocyte elastase during hemodialysis: effects of different dialyzer membranes.
    Hörl WH; Steinhauer HB; Schollmeyer P
    Kidney Int; 1985 Nov; 28(5):791-6. PubMed ID: 3878906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dialyzer geometry on granulocyte and complement activation.
    Schaefer RM; Heidland A; Hörl WH
    Am J Nephrol; 1987; 7(2):121-6. PubMed ID: 3496792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of different dialyzers on proteinases and proteinase inhibitors during hemodialysis.
    Hörl WH; Schaefer RM; Heidland A
    Am J Nephrol; 1985; 5(5):320-6. PubMed ID: 2414989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of main granulocyte components during hemodialysis: effects of immunosuppression.
    Riegel W; Leverenz K; Schollmeyer P; Wilms H; Hörl WH
    Nephron; 1987; 46(2):161-6. PubMed ID: 3037400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-2-microglobulin and main granulocyte components in hemodialysis patients.
    Haag-Weber M; Schollmeyer P; Hörl WH
    Artif Organs; 1989 Apr; 13(2):92-6. PubMed ID: 2650660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of main granulocyte components during hemodialysis. Comparison of new and reused dialyzers.
    Hörl WH; Feinstein EI; Wanner C; Frischmuth N; Gösele A; Massry SG
    Am J Nephrol; 1990; 10(1):53-7. PubMed ID: 2343881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of main granulocyte components during cardiopulmonary bypass.
    Riegel W; Spillner G; Schlosser V; Hörl WH
    J Thorac Cardiovasc Surg; 1988 Jun; 95(6):1014-9. PubMed ID: 2836662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of main granulocyte components during hemodialysis.
    Hörl WH; Riegel W; Steinhauer HB; Wanner C; Schollmeyer P; Schaefer RM; Heidland A
    Contrib Nephrol; 1987; 59():35-43. PubMed ID: 2832120
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement of dialyzer compatibility by reduction of membrane surface area.
    Schaefer RM; Rautenberg W; Neumann S; Heidland A; Hörl WH
    Clin Nephrol; 1986; 26 Suppl 1():S35-8. PubMed ID: 3644705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary report on complement activating potential of polycarbonate membrane.
    Henderson LW; Chenoweth DE; Shinaberger JH; Miller J; Konstantin P
    Blood Purif; 1986; 4(1-3):74-81. PubMed ID: 3730164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced biocompatibility with a new cellulosic membrane: Cuprophan versus Hemophan.
    Schaefer RM; Hörl WH; Kokot K; Heidland A
    Blood Purif; 1987; 5(4):262-7. PubMed ID: 3426830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes.
    Chenoweth DE; Cheung AK; Henderson LW
    Kidney Int; 1983 Dec; 24(6):764-9. PubMed ID: 6609269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte activation during haemodialysis in the absence of complement activation: inhibition by calcium channel blockers.
    Haag-Weber M; Schollmeyer P; Hörl WH
    Eur J Clin Invest; 1988 Aug; 18(4):380-5. PubMed ID: 3139423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient reactions and granulocyte degranulation during hemodialysis with cuprophane and polycarbonate membranes. A double-blind study.
    Danielson BG; Hällgren R; Venge P
    Blood Purif; 1986; 4(1-3):147-50. PubMed ID: 3524607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of a new high-flux cellulose acetate membrane.
    Schaefer RM; Huber L; Gilge U; Bausewein K; Vienken J; Heidland A
    Int J Artif Organs; 1989 Feb; 12(2):85-90. PubMed ID: 2651325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms and activation of granulocytes and complement with two dialysis membranes.
    Ivanovich P; Chenoweth DE; Schmidt R; Klinkmann H; Boxer LA; Jacob HS; Hammerschmidt DE
    Kidney Int; 1983 Dec; 24(6):758-63. PubMed ID: 6609268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced plasma and intracellular levels of main granulocyte components in diabetics on dialysis.
    Hörl WH; Schaefer RM; Wanner C; Bahlmann J; Reitinger J; Schollmeyer P; Heidland A
    Blood Purif; 1989; 7(6):314-23. PubMed ID: 2482056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.